A further TWEAK to multiple sclerosis pathophysiology

Molecular Neurobiology

Volumn 49, Issue 1, 2014, Pages 78-87

  Nazeri, Arash ^a,b   Heydarpour, Pouria ^a,b   Sadaghiani, Shokufeh ^a,b   Sahraian, Mohammad Ali ^b   Burkly, Linda C ^c   Bar Or, Amit ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BIOGEN   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

EAE; Fn14; Multiple sclerosis; TWEAK

Indexed keywords

CASPASE 3; CELL SURFACE RECEPTOR; CHEMOKINE; CYTOKINE; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; FIBROBLAST GROWTH FACTOR INDUCIBLE 14 FC RECEPTOR DECOY PROTEIN; FIBROBLAST GROWTH FACTOR INDUCIBLE 14 TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; GAMMA INTERFERON; GELATINASE B; HYBRID PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEAR FACTOR KAPPA B INDUCING KINASE; PDL 102; PHOSPHOTRANSFERASE; RO 5458640; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ASTROCYTE; ASTROCYTOSIS; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE RELEASE; DEMYELINATION; ENDOTHELIUM CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SPINAL CORD LESION; WHITE MATTER LESION;

ANIMALS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 84894346803     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8490-y     Document Type: Review

References (81)

1. Nylander A, Hafler DA (2012) Multiple sclerosis. J Clin Invest 122(4):1180-1188. doi: 10.1172/JCI58649
2. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C (2011) Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365(23):2188-2197
3. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L (2006) TWEAK is a novel arthritogenic mediator. J Immunol 177(4):2610-2620
4. Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H, Okumura K (2006) Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol 177(9):6433-6439
5. Michaelson JS, Wisniacki N, Burkly LC, Putterman C (2012) Role of TWEAK in lupus nephritis: a bench-to-bedside review. Journal of Autoimmunity
6. Dohi T, Burkly LC (2012) The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases; focus on inflammatory bowel diseases. J Leukoc Biol 92(2):265-279
7. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Moreno JA, Meilhac O, Ortiz A, Egido J (2007) TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Front Biosci 12:3648-3655
8. Sanz AB, Sanchez-Niño MD, Ortiz A (2011) TWEAK, a multifunctional cytokine in kidney injury. Kidney international
9. Kumar A, Bhatnagar S, Paul PK (2012) TWEAK and TRAF6 regulate skeletal muscle atrophy. Current Opinion in Clinical Nutrition & Metabolic Care 15(3):233
10. Winkles JA, Tran NL, Berens ME (2006) TWEAK and Fn14: new molecular targets for cancer therapy? Cancer Lett 235(1):11-17
11. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272(51):32401-32410
12. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E, Yang B, Daniel D, Ashkenazi A (2005) TWEAK attenuates the transition from innate to adaptive immunity. Cell 123(5):931-944. doi: 10.1016/j.cell.2005.09.022
13. Burkly LC, Michaelson JS, Zheng TS (2011) TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 244(1):99-114. doi: 10.1111/j.1600-065X.2011.01054.x
14. Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, Izui S, Chicheportiche Y, Boucraut J (2002) TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 133(1-2):116-123
15. Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H (2000) Involvement of TWEAK in Interferon γ-stimulated monocyte cytotoxicity. The Journal of experimental medicine 192(9):1373-1380
16. Winkles JA (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7(5):411-425. doi: 10.1038/nrd2488
17. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, Ambrose C, Tschopp J, Schneider P (2006) Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281(20):13964-13971. doi: 10.1074/jbc.M601553200
18. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA, Fanslow WC (2001) A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15(5):837-846
19. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang MZ, Maurer MH, Rossner M, Schneider A, Schwaninger M (2004) Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 24(38):8237-8244
20. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS (2007) TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 40(1):1-16. doi: 10.1016/j.cyto.2007.09.007
21. Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, Winkles JA, Michaelson JS, Allaire N, Schneider P (2006) TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 25(24):5826-5839
22. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, Browning B, Michaelson JS, Baestcher M, Wang B (2005) TWEAK induces liver progenitor cell proliferation. J Clin Invest 115(9):2330-2340
23. Brown SA, Hanscom HN, Vu H, Brew SA, Winkles JA (2006) TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J 397(2):297-304. doi: 10.1042/BJ20051362
24. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S (2003) TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 278(38):36005-36012. doi: 10.1074/jbc.M304266200
25. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R (2007) A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 178(12):8183-8194
26. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK (2001) Identification of the haemoglobin scavenger receptor. Nature 409(6817):198-201. doi: 10.1038/35051594
27. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, Paramo JA, Ortega L, Egido J, Blanco-Colio LM (2009) The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 207(1):103-110. doi: 10.1016/j.atherosclerosis. 2009.04.033
28. Fick A, Lang I, Schäfer V, Seher A, Trebing J, Weisenberger D, Wajant H (2012) Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem 287(1):484-495
29. Yepes M (2007) TWEAK and the central nervous system. Mol Neurobiol 35(3):255-265
30. Constantinescu CS, Farooqi N, O'Brien K, Gran B (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164(4):1079-1106. doi: 10.1111/j.1476-5381.2011.01302.x
31. Desplat-Jego S, Creidy R, Varriale S, Allaire N, Luo Y, Bernard D, Hahm K, Burkly L, Boucraut J (2005) Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 117(1):15-23. doi: 10.1016/j.clim.2005.06.005
32. Mueller AM, Pedre X, Kleiter I, Hornberg M, Steinbrecher A, Giegerich G (2005) Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 159(1-2):55-65. doi: 10.1016/j.jneuroim.2004.10.001
33. Kipp M, Clarner T, Dang J, Copray S, Beyer C (2009) The cuprizone animal model: new insights into an old story. Acta neuropathologica 118(6):723-736
34. Iocca HA, Plant SR, Wang Y, Runkel L, O'Connor BP, Lundsmith ET, Hahm K, van Deventer HW, Burkly LC, Ting JP (2008) TNF superfamily member TWEAK exacerbates inflammation and demyelination in the cuprizone-induced model. J Neuroimmunol 194(1-2):97-106. doi: 10.1016/j.jneuroim.2007.12.003
35. Razmara M, Hilliard B, Ziarani AK, Murali R, Yellayi S, Ghazanfar M, Chen YH, Tykocinski ML (2009) Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol 174(2):460-474. doi: 10.2353/ajpath.2009.080462
36. Prinz-Hadad H, Mizrachi T, Irony-Tur-Sinai M, Prigozhina TB, Aronin A, Brenner T, Dranitzki-Elhalel M (2013) Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14.TRAIL. J Neuroinflammation 10:36
37. Desplat-Jego S, Feuillet L, Creidy R, Malikova I, Rance R, Khrestchatisky M, Hahm K, Burkly LC, Pelletier J, Boucraut J (2009) TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol 85(1):132-135. doi: 10.1189/jlb.0608347
38. Burkly LC, Dohi T (2011) The TWEAK/Fn14 pathway in tissue remodeling: for better or for worse. Adv Exp Med Biol 691:305-322. doi: 10.1007/978-1-4419- 6612-4-32
39. Serafini B, Magliozzi R, Rosicarelli B, Reynolds R, Zheng TS, Aloisi F (2008) Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury. J Neuropathol Exp Neurol 67(12):1137-1148. doi: 10.1097/NEN.0b013e31818dab90
40. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ (2003) Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 62(7):723-732
41. Calabrese M, Filippi M, Gallo P (2010) Cortical lesions in multiple sclerosis. Nat Rev Neurol 6(8):438-444. doi: 10.1038/nrneurol.2010.93
42. Kutzelnigg A, Lassmann H (2006) Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits? J Neurol Sci 245(1-2):123-126. doi: 10.1016/j.jns.2005.09.021
43. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130(Pt 4):1089-1104. doi: 10.1093/brain/awm038
44. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128(Pt 11):2705-2712. doi: 10.1093/brain/awh641
45. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K (2002) Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 299(3):488-493
46. Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M, Desplat-Jego S, Chicheportiche Y, Dietrich PY (2000) TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 32(1):102-107. doi: 10.1002/1098-1136(200010) 32:1<102::AID-GLIA100>3.0.CO;2-U
47. Stephan D, Sbai O, Wen J, Couraud PO, Putterman C, Khrestchatisky M, Desplat-Jego S (2013) TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier. J Neuroinflammation 10:9. doi: 10.1186/1742-2094-10-9
48. Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2(7):502-511. doi: 10.1038/35081571
49. Yong VW (2005) Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 6(12):931-944. doi: 10.1038/nrn1807
50. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K (1999) Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122(Pt 2):191-197
51. Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V (2006) Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg 108(2):124-128. doi: 10.1016/j.clineuro.2005.01.005
52. Gray E, Thomas TL, Betmouni S, Scolding N, Love S (2008) Elevated matrix metalloproteinase-9 and degradation of perineuronal nets in cerebrocortical multiple sclerosis plaques. J Neuropathol Exp Neurol 67(9):888
53. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, Van der Valk P, De Groot CJ (1997) Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 94(6):590-598
54. Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, van den Oord J, Sciot R, Meinhardt T, Hammerling G, Opdenakker G, Arnold B (1999) Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 104(11):1507-1515. doi: 10.1172/JCI6886
55. Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F, Tomassini V, Pozzilli C, Stecchi S, Giaquinto P, Livrea P, Trojano M (2005) Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 11(4):441-446
56. Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim DI, Park YB, Kwon BS, Park JE, Lee WH (2004) TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 68(4):396-399
57. Polavarapu R, Gongora MC, Winkles JA, Yepes M (2005) Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation. J Neurosci 25(44):10094-10100. doi: 10.1523/JNEUROSCI.3382-05.2005
58. Zhang X, Winkles JA, Gongora MC, Polavarapu R, Michaelson JS, Hahm K, Burkly L, Friedman M, Li XJ, Yepes M (2007) TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab 27(3):534-544. doi: 10.1038/sj.jcbfm.9600368
59. Li H, Mittal A, Paul PK, Kumar M, Srivastava DS, Tyagi SC, Kumar A (2009) Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J Biol Chem 284(7):4439-4450. doi: 10.1074/jbc.M805546200
60. Moore CS, Abdullah SL, Brown A, Arulpragasam A, Crocker SJ (2011) How factors secreted from astrocytes impact myelin repair. J Neurosci Res 89(1):13-21. doi: 10.1002/jnr.22482
61. Williams A, Piaton G, Lubetzki C (2007) Astrocytes - friends or foes in multiple sclerosis? Glia 55(13):1300-1312. doi: 10.1002/glia.20546
62. Nair A, Frederick T, Miller S (2008) Astrocytes in multiple sclerosis: a product of their environment. Cellular and Molecular Life Sciences 65(17):2702-2720. doi: 10.1007/s00018-008-8059-5
63. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA (2012) Genomic analysis of reactive astrogliosis. J Neurosci 32(18):6391-6410. doi: 10.1523/jneurosci.6221-11.2012
64. Rousselet E, Traver S, Monnet Y, Perrin A, Mandjee N, Hild A, Hirsch EC, Zheng TS, Hunot S (2012) Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) induces astrocyte proliferation through the activation of transforming growth factor (TGF)-α/epidermal growth factor receptor (EGFR) signaling pathway. Mol Pharmacol. doi: 10.1124/mol.112.079608
65. Mc Guire C, Beyaert R, van Loo G (2011) Death receptor signalling in central nervous system inflammation and demyelination. Trends Neurosci 34(12):619-628. doi: 10.1016/j.tins.2011.09.002
66. Haile WB, Echeverry R, Wu F, Guzman J, An J, Wu J, Yepes M (2010) Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death. Neuroscience 171(4):1256-1264. doi: 10.1016/j.neuroscience.2010.10.029
67. Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, Kominami E, Okumura K, Yagita H (2002) Multiple pathways of TWEAK-induced cell death. J Immunol 168(2):734-743
68. Wang D, Fung JN, Tuo Y, Hu L, Chen C (2010) TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway. Cancer Lett 294(1):91-100. doi: 10.1016/j.canlet.2010.01.027
69. Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, Egido J, Ortiz A (2006) Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 70(10):1750-1758. doi: 10.1038/sj.ki.5001866
70. Bhatnagar S, Mittal A, Gupta SK, Kumar A (2012) TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. J Cell Physiol 227(3):1042-1051
71. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM, Dawson VL (2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297(5579):259-263. doi: 10.1126/science.1072221
72. Cavone L, Aldinucci A, Ballerini C, Biagioli T, Moroni F, Chiarugi A (2011) PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity. Mult Scler 17(7):794-807. doi: 10.1177/1352458511399113
73. Chiarugi A (2002) Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br J Pharmacol 137(6):761-770. doi: 10.1038/sj.bjp.0704934
74. Scott GS, Kean RB, Mikheeva T, Fabis MJ, Mabley JG, Szabo C, Hooper DC (2004) The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)- N, N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther 310(3):1053-1061. doi: 10.1124/jpet.103.063214
75. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL (2009) Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 10(9):958-964. doi: 10.1038/ni.1775
76. Echeverry R, Wu F, Haile WB, Wu J, Yepes M (2012) The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system. J Neuroinflammation 9:45. doi: 10.1186/1742-2094-9-45
77. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47(6):1531-1534
78. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) Neurology 53(3):457-465
79. Michaelson JS, Wisniacki N, Burkly LC, Putterman C (2012) Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmun 39(3):130-142. doi: 10.1016/j.jaut.2012.05.003
80. Wisniacki N, Chindalore VL, Codding CE, Greenwald MW, Shaw ML, Fitilev S, Ershova O, Hu X, Zheng TS, Amaravadi L A Phase I, randomized, double-blind, placebo-controlled, single dose, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of BIIB023 (anti-TWEAK) in subjects with rheumatoid arthritis. In: Arthritis and rheumatism, 2011. Wiley-Blackwell, MALDEN, pp S858-S858
81. Yepes M, Brown SA, Moore EG, Smith EP, Lawrence DA, Winkles JA (2005) A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 166(2):511-520. doi: 10.1016/S0002-9440(10)62273- 0